Diligence memo · auto-generated · as of July 2, 2026
Tetherex Pharmaceuticals Corp
Tetherex Pharmaceuticals Corp looks fair against its niche peers and is dormant on financing cadence.
Businessfiled
Tetherex Pharmaceuticals Corp operates in Biotechnology, based in OKLAHOMA CITY.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Tetherex Pharmaceuticals Corp has raised $48M in disclosed capital across 3 recorded rounds, aggregated from public filings. Its latest round is modeled as Series C (a $40M–$100M round).
Largest single filing: $43M on 2018-02-20.
Most recent recorded round closed around 2018-02-20.
Valuation (modeled)modeled
Provath models Tetherex Pharmaceuticals Corp at approximately $1.8B (range $133M–$4.6B). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Fair. Modeled value is 0.86× the median modeled value of Series C Biotechnology companies in 2016–2018 (41 peers) — value vs value, same stage and era. Within the normal band (86% of peer median) for its niche.
Financing rhythm & timingmixed
Historic cadence: a new round about every 12 months.
Last raise 8.4 yr ago; this sector typically re-raises about every 14 months.
Silent for over 3× the sector's normal cadence.
The last round stepped up 71.6× from the prior — scaling.
Comparablesmixed
Capital scale ranks ahead of 81% of Biotechnology peers (4293 compared).
Modeled value ranks above 93% of those peers.
Closest niche peers: Genesis Biopharma, Inc, Alder Biopharmaceuticals Inc, Ideaya Biosciences, Inc., Stoke Therapeutics, Inc., 4D Molecular Therapeutics Inc.
Peoplefiled
10 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.